Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Simcere Pharmaceutical

China: Engagement strategies

As China grows apace, digital is increasingly being used to engage both customers and patients

- PMLiVE

ACC and Boehringer develop CME programme in China

Will focus on stroke prevention in atrial fibrillation

- PMLiVE

WuXi Pharmatech and OMT expand antibodies agreement

Enables Chinese CRO to increase its service offering

- PMLiVE

Lilly abandons tabalumab for rheumatoid arthritis

Decision based on lack of efficacy in late-stage trials

- PMLiVE

Biosimilars in China

Tipping the balance: risks and opportunities in biosimilars

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

- PMLiVE

Takeda launches new business in China

Will serve as hub for importing medicines from across the world

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

UCB launches arthritis exercise programme in the UK

Scheme was piloted at two NHS Trusts during 2011

WuXi and PRA form Chinese joint venture

Combine to form new China-focused independentCRO

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links